Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
(Summary)Consolidated Financial Results for the Nine Months Ended October 31, 2025 [Under Japanese GAAP]
Tri Chemical, Feb-Oct (Cumulative 3Q) Ordinary Profit Increases by 25%
Notice Regarding the Execution of a Term-Loan Agreement with a Commitment Period and a Commitment-Line Agreement with a Term-Out Option
Notice Regarding the Establishment of a Joint Venture in China
Notice Concerning Revisions to Full-Year Financial Results Forecasts
Summary of Consolidated Financial Results for the Six Months Ended July 31, 2025 [Japanese GAAP]
Tri Chemical, Ordinary Profit Forecast for the Fiscal Year Revised Downward to an Unexpected 1% Decrease
Tri Chemical, Feb-Apr (1Q) Ordinary Profit Increases by 54%
Summary of Consolidated Financial Results for the Three Months Ended April 30, 2025 [Japanese GAAP]
Notice Regarding the Signing of a Memorandum of Understanding
(Update on Disclosure) Notice Regarding Construction of New Plant
Tri Chemical, 5% Increase in Ordinary Profit, Update Record High for Second Consecutive Term, Increased Previous Year's Dividend by 5 yen, Plan to Continue the 35 yen Policy This Fiscal Year as Well
Summary of Consolidated Financial Results for the Fiscal Year Ended January 31, 2025 [Japanese GAAP]
Tri Chemical, Last Fiscal Year Ordinary Profit Revised Upward by 18%, Highest in Two Terms
[Delayed] Summary of Consolidated Financial Results for the Nine Months Ended October 31, 2024 [Japanese GAAP]
Tri Chemical Laboratories Inc., February-October (Third Quarter Cumulative) Ordinary Profit Increases by 78%, August-October Ordinary Profit Increases by 3.1 times
[Delayed] Summary of Consolidated Financial Results for the Six Months Ended July 31, 2024 [Japanese GAAP]
Tri Chemical Laboratories Inc., The Current Fiscal Year Ordinary Profit Revised Upward by 15%